Real world outcomes of patients with relapsed/refractory prolymphocytic progression of CLL and splenic B-cell lymphoma/leukaemia with prominent nucleoli and the role of novel agents

This study will be an international multicentre retrospective study of patients with r/r prolymphocytic progression of CLL/SLL and SBLPN.

Update 20 July 2023 – Ongoing data collection at 4 sites (SCGH, FSH, PMCC, Brisbane site), Awaiting application at SCGH for RGS/HREC approval once pathway established, Ongoing discussion with additional sites to see if another few sites might be interested in participating.

Update 24 November 2023 – Sites have data, waiting on approval to get DTA’s completed

Update 20 January 2026 – Sophie Zeng (registrar leading the project) has final resubmission to sent to Research at Monash Health within the next 6 weeks addressing final queries. Aim to get approval in the next few months.  DTAs to be worked on. Sites to be contacted in coming month once Research approval at MH.

Update 18 May 2026 – Project has been handed back to RS as registrar unable to progress the project. He will complete the resubmission to Research at Monash Health within the next 4 weeks addressing final queries. Have reached out to sites to apologise for delay.  DTAs to be worked on. Sites to be contacted in coming month once Research approval at MH

Update 17 Sept 2026 – Ethics approved, awaiting some DTA’s. May need to recruit more sites. Moving along currently.